( July 2, 2025, 2:37 PM EDT) -- WASHINGTON, D.C. — A Federal Circuit U.S. Court of Appeals panel held that the U.S. Patent Trial and Appeal Board (PTAB) erred while construing a claim phrase during inter partes review (IPR) proceedings regarding an eye redness medication; the panel reversed the PTAB’s claim construction and vacated a finding of obviousness that stemmed from it....